Molecular Modeling of Prion Transmission to Humans
Etienne Levavasseur,
Nicolas Privat,
Juan-Carlos Espinosa Martin,
Steve Simoneau,
Thierry Baron,
Benoit Flan,
Juan-Maria Torres,
Stéphane Haïk
Affiliations
Etienne Levavasseur
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ. Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013 Paris, France
Nicolas Privat
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ. Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013 Paris, France
Juan-Carlos Espinosa Martin
Centro de Investigacion en Sanidad Animal, Carretera de Algete a El Casar, 28130 Madrid, Spain
Steve Simoneau
LFB Biomédicaments, 91958 Les Ulis, France
Thierry Baron
Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES), Unité Maladies neurodégénératives, 69394 Lyon, France
Benoit Flan
LFB Biomédicaments, 91958 Les Ulis, France
Juan-Maria Torres
Centro de Investigacion en Sanidad Animal, Carretera de Algete a El Casar, 28130 Madrid, Spain
Stéphane Haïk
Inserm U 1127, CNRS UMR 7225, Sorbonne Universités, UPMC Univ. Paris 06 UMR S 1127, Institut du Cerveau et de la Moelle épinière, ICM, 75013 Paris, France
Using different prion strains, such as the variant Creutzfeldt-Jakob disease agent and the atypical bovine spongiform encephalopathy agents, and using transgenic mice expressing human or bovine prion protein, we assessed the reliability of protein misfolding cyclic amplification (PMCA) to model interspecies and genetic barriers to prion transmission. We compared our PMCA results with in vivo transmission data characterized by attack rates, i.e., the percentage of inoculated mice that developed the disease. Using 19 seed/substrate combinations, we observed that a significant PMCA amplification was only obtained when the mouse line used as substrate is susceptible to the corresponding strain. Our results suggest that PMCA provides a useful tool to study genetic barriers to transmission and to study the zoonotic potential of emerging prion strains.